Healthcare Industry News: Penumbra
News Release - April 21, 2017
Penumbra, Inc. Appoints Bridget O'Rourke to its Board of DirectorsALAMEDA, Calif., April 21, 2017 -- (Healthcare Sales & Marketing Network) -- Penumbra, Inc. (NYSE: PEN) today announced that Bridget O'Rourke has been appointed to its Board of Directors, effective immediately.
"We are thrilled to be adding Bridget to our board. She brings to the board a strong background of developing executive talent and financial experience, a skill set that will prove invaluable as we continue to grow as a company. The board and management will benefit greatly from working with Bridget and learning from her expertise," said Adam Elsesser, Chairman, Chief Executive Officer and President.
With the arrival of Ms. O'Rourke, the Penumbra Board of Directors will be comprised of six directors, four of whom are independent. Ms. O'Rourke will serve as a member of the Audit, Compensation and Nominating and Corporate Governance Committees.
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on interventional therapies. Penumbra designs, develops, manufactures and markets innovative devices and has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.